Combinostics new PET quantification application cNeuro cPET receives FDA 510(k) clearance
New cPET application for amyloid and FDG brain PET quantification further extends Combinostics’ solutions across the entire patient pathway for neurological disorders and supports end-to-to-end workflows.
